Table 2. Comparison of the outcomes of the 260 series group and 290 series group patients matched according to propensity scores.
| 260 series N = 187 | 290 series N = 374 | OR/Coefficient (95 % CI) | P value | |
| Patients with at least one adenoma | 83 (44.4 %) | 173 (46.3 %) | 1.1 (0.76, 1.5) | 0.67 |
| No. of adenomas per patient 1 | 0.83 (1.3) | 0.90 (1.4) | 0.070 (-0.17, 0.31) | 0.57 |
| No. of cancers per patient 1 | 0.005 (0.073) | 0.005 (0.073) | –0.0 (–0.013, 0.013) | 1.00 |
| No. of advanced adenomas per patient 1 | 0.027 (0.16) | 0.032 (0.19) | 0.005 (-0.027, 0.037) | 0.74 |
| No. of adenomas in the right colon per patient 1 | 0.59 (1.1) | 0.68 (1.1) | 0.096 (-0.099, 0.29) | 0.34 |
| No. of adenomas ≤ 5 mm per patient 1 | 0.74 (1.3) | 0.79 (1.2) | 0.043 (-0.17, 0.26) | 0.70 |
| No. of flat adenomas per patient 1 | 0.61 (1.1) | 0.81 (1.3) | 0.20 (–0.015, 0.42) | 0.07 |
| Patients with at least one sessile serrated polyp | 2 (1.1 %) | 24 (6.4 %) | 6.3 (1.5, 27) | 0.01 |
| No. of sessile serrated polyps per patient 1 | 0.011 (0.15) | 0.078 (0.31) | 0.067 (0.019, 0.11) | < 0.01 |
| Insertion time 1 , min | 5.9 (5.1) | 4.1 (1.9) | –1.8 ( 2.4, –1.2) | < 0.0001 |
| Withdrawal time 1 , min | 15.8 (4.7) | 13.1 (2.9) | –2.8 ( 3.4, –2.1) | < 0.0001 |
| Use of pethidine hydrochloride | 98 (52.4 %) | 173 (46.3 %) | 0.78 (0.55, 1.1) | 0.17 |
| Use of midazolam | 163 (87.2 %) | 306 (81.8 %) | 0.66 (0.40, 1.1) | 0.11 |
Odds ratios using logistic regression model were calculated for categorical variables and regression coefficients of linear regression model were calculated for continuous variables. The regression coefficients were obtained by subtracting the mean values of 260 series from that of 290 series. P values were calculated by the Wald test using logistic regression. OR: odds ratio, CI: confidence interval.
1
Mean (standard deviation).